Global Angina Pectoris Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

The Market is segmented by Therapeutic Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets and Others) and Geography

Market Snapshot

Angina Pectoris Drugs Market-1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

3.2%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Lifestyle diseases and their chronic nature is among the pivotal reason for the high cardiovascular-related disorders globally. As per the Nesia Foundation Hospital, globally, about 14.2 million people between the age group 30-69 years, die prematurely from lifestyle disorders such as diabetes, arteriosclerosis, high cholesterol, stroke, nephritis, cancer, and several others. As per several published data on lifestyle-related diseases, women have more atypical signs of heart attack more often than men. In addition, in several cases, there is increased misdiagnosis or delayed diagnosis which eliminate the likeliness to receive immediate life-saving treatment of primary angioplasty and stents. The increasing burden of lifestyle diseases directly impacts the socio-economic aspects of nations globally, where appropriate actions for their management is the need of the moment. Thus, increasing burden of lifestyle diseases majorly drives the demand and need for angina pectoris drugs market.

Scope of the Report

As per the scope of the report, Angina pectoris refers to a strangling or pressure-like pain caused by cardiac ischemia. Angina drugs are the initial treatment of angina pectoris. The antianginal drugs recommended for initial treatment are β blockers and calcium channel blockers, which reduce myocardial ischemia by heart rate reduction and vasodilatory mechanisms, respectively. Either or both of these drug classes should be prescribed, together with a short-acting nitrate for prompt alleviation of angina attacks.

By Therapeutic Class
Beta Blockers
Calcium Channel Blockers
Nitrates
Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)
Anti-Platelets
Others
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Beta Blockers is Expected to Hold Smallest Share of Global Angina Pectoris Drugs Market, Over the forecast period

Beta blockers work by blocking the effect of adrenaline on the heart by providing benefits such as Slowing of the heart rate and reducing the force of heart muscle contraction. In patients with stable angina caused by CAD, beta blockers are considered first-line therapy. Beta Blockers has the smallest share in the market as the majority of beta-blocker drugs are predominately generic with key patent expirations impacting GlaxoSmithKline’s Coreg and AstraZeneca’s Toprol. Post Pfizer’s Norvasc patent being determined invalid in 2007, the Calcium Antagonist market is predominantly generic as well.

Angina Pectoris Drugs Market-2

To understand key trends, Download Sample Report

North America Region Holds the Largest Market Share of Angina Pectoris Drugs Market

North America dominates the Angina Pectoris Drugs market due to the established healthcare infrastructure, increased adoption of therapeutics and presence of key manufacturers in the U.S are responsible for its large share. Ischaemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging. Moreover, increasing incidence of cardiac disorders due to the sedentary lifestyle and favorable regulatory initiatives are fueling the market growth.

Angina Pectoris Drugs Market-3

To understand geography trends, Download Sample Report

Competitive Landscape

Some of the prominent industry players operating in total Angina Pectoris Drugs market include Amgen, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline Plc and Merck & Co., Inc. Development of advanced products for better outcomes and rigorous marketing are some of the competitive strategies adopted by market players.

Major Players

  1. Amgen
  2. Bayer AG
  3. Eli Lilly and Company
  4. Gilead Sciences
  5. GlaxoSmithKline Plc.

* Complete list of players covered available in the table of contents below

Angina Pectoris Drugs Market-4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Lifestyles Diseases

      2. 4.2.2 Technological Advancements towards Personalized Cardiovascular Medicines

      3. 4.2.3 Augmentation of Novel Drug Delivery Systems

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Adoption of Minimally Invasive Surgeries

      2. 4.3.2 Side Effects Associated with Certain Drug Classes

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapeutic Class

      1. 5.1.1 Beta Blockers

      2. 5.1.2 Calcium Channel Blockers

      3. 5.1.3 Nitrates

      4. 5.1.4 Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors)

      5. 5.1.5 Anti-Platelets

      6. 5.1.6 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 US

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 UK

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen

      2. 6.1.2 Bayer AG

      3. 6.1.3 Eli Lilly and Company

      4. 6.1.4 Gilead Sciences

      5. 6.1.5 GlaxoSmithKline Plc.

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Novartis AG

      8. 6.1.8 Otsuka Pharmaceutical Co. Ltd

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Sanofi

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information